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httpObjectives: The purpose of this systematic review was to examine whether magnetic resonance imaging (MRI) or
computed tomography angiography (CTA) is more sensitive for the detection of endoleaks in patients with
abdominal aortic aneurysm (AAA) after EVAR.
Design: Systematic review.
Materials and methods: A systematic electronic search was performed. Articles were included when post-EVAR
patients were evaluated by both MRI as index test and CTA as comparison. Methodological quality was assessed
with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. Primary outcome was the proportion
of patients in whom MRI detected additional endoleaks, which were not seen with CTA.
Results: Eleven articles were included. The overall methodological quality of the articles was good. In total, 369
patients with 562 MRI and 562 CTA examinations were included. A total of 146 endoleaks were detected by CTA;
MRI detected all but two of these endoleaks. With MRI 132 additional endoleaks were found.
Conclusions: MRI is more sensitive compared to CTA for the detection of post-EVAR endoleaks, especially for the
detection of type II endoleaks. MRI should be considered in patients with continued AAA growth and negative or
uncertain ﬁndings at CTA.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Abdominal aortic aneurysmBrief statementThis systematic review demonstrates that magnetic reso-
nance imaging (MRI) detects signiﬁcantly more endoleaks
compared to computed tomography angiography (CTA) in
patients after abdominal endovascular aneurysm repair
(EVAR). These additional endoleaks detected by MRI are
mainly type II endoleaks. In patients with aneurysm growth,
these type II endoleaks require treatment according to the
current guidelines. MRI is a complementary imaging
modality to CTA that must be considered especially in
patients with post-EVAR abdominal aortic aneurysm (AAA)
growth of unknown origin.
The aim of endovascular aortic aneurysm repair (EVAR) is
to prevent aneurysm rupture by exclusion of the aneurysm
sac from the systemic circulation. A successful endovascular
procedure will result in depressurisation of the aneurysm sacrresponding author. Tel.: þ31 887556689; fax: þ31 302581098.
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://dx.doi.org/10.1016/j.ejvs.2012.12.014and arrest of abdominal aortic aneurysm (AAA) growth.1,2 A
clinically important complication after EVAR is the occurrence
of endoleak. Endoleak is deﬁned as leakage of blood into the
aneurysm sac, which may result in continued aneurysm
growth and, ultimately, rupture. Endoleaks are classiﬁed into
different types (Table 1).3 Correct endoleak classiﬁcation is
important because there are different treatment strategies
for different endoleak subtypes.3,4
For the detection of complications after EVAR, post-
operative surveillance is advised by performing computed
tomography angiography (CTA) and plain radiography
within 1 month.3 If an endoleak is detected, CTA and plain
radiography are advised after 6 and 12 months and yearly
thereafter. If no endoleak is detected at 1 month, CTA is
advised after 12 months followed by yearly abdominal
duplex ultrasound and plain radiography.4 In current
guidelines digital subtraction angiography (DSA) has no
diagnostic role during EVAR follow-up.4 However, in
patients with inconclusive imaging follow-up or in patients
with an endoleak that requires treatment, DSA is recom-
mended but often not performed.
Table 1. Endoleak classiﬁcation.3
Endoleak type Description
I Attachment site leak e IA proximal,
IB is distal, IC Iliac occluder
II Branch vessel retrograde ﬂow e
IIA IMA; IIB Lumbar arteries
III Graft Failure
IV Graft-wall porosity
V Endotension
IMA ¼ Inferior Mesenteric Artery.
J. Habets et al. 341Currently, tri-phasic CTA with unenhanced, arterial and
delayed phases is considered to be the most appropriate
method for detection of endoleaks after EVAR. Neverthe-
less, it is known that CTA sometimes fails to detect the
presence of endoleaks.5,6 In patients with aneurysm growth
post-EVAR, it is important to detect these missed endoleaks
with alternative imaging strategies because they may
require treatment.4,7,8 Because of its excellent soft-tissue
contrast, magnetic resonance imaging (MRI) is of high
interest for this purpose. On the other hand, it is conceiv-
able that susceptibility artefacts associated with the stent-
graft material limit assessment of post-EVAR AAA with MRI.
At present, the diagnostic capabilities of MRI for the
detection of endoleak after EVAR remain to be determined.
The purpose of this systematic review is to examine
whether MRI is more sensitive than CTA for the detection of
endoleaks in patients with AAA after EVAR.
MATERIALS AND METHODS
Literature search
A systematic electronic search was performed in the PubMed
and Embase databases for original articles published until 1
November 2011. The language was restricted to English arti-
cles. Key search terms were ‘magnetic resonance imaging’,
‘endoleak’, ‘endovascular treatment’ and corresponding
synonyms. The exact search terms are shown in Appendix I.Selection of publications
After removal of duplicates, two reviewers independently
screened titles and abstracts of the remaining studies. Arti-
cles were included if: (1) patients after EVAR of an abdominal
aortic aneurysmwere studied; (2) examination during follow-
up for the detection of endoleaks included assessment with
MRI; and (3) a comparison between ﬁndings at MRI and CTA
was performed. Full-text versions of studies thatmatched the
inclusion criteria were obtained. The reference lists of all
included articles were scanned by the ﬁrst authors for any
relevant publication not identiﬁed by the electronic searches
(cross-referencing); if present, these articles were included.
All full-text publications were examined by two reviewers
independently and in cases of disagreement consensus was
reached during a consensus meeting.Quality assessment
Information on study design characteristics, sample size and
type of patient population, MRI protocol, CTA protocol aswell as the number and type of endoleaks detected by MRI
and CTA was collected.
Studies were assessed for quality based on the criteria as
proposed by the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) checklist.9 The QUADAS items for each
included study were scored as ‘yes’, ‘no’ and ‘unclear’
(Appendix II).Data analysis
OnMRI examinations, endoleakwas deﬁned as a high-intensity
signal within the aneurysm sac on post-contrast T1-weighted
images, not present on pre-contrast T1-weighted images.
The outcome in the ﬁrst set of analyses was the proportion
of patients in whom an endoleak was detected byMRI, which
was not detected by CTA, divided by the total number of
patients examined. In case a study reported results of MRI
versus CTA examination during follow-up from multiple time
points, we used all available data.10 A Forest plot was
generated to depict the proportion of additional endoleaks
detected byMRI and corresponding 95% conﬁdence intervals
(CIs) for all studies. To evaluate if data could be pooled, we
calculated I2 and the Cochran’s Q test to examine how
consistent the proportion of additionally detected endoleaks
by MRI was across studies. I2 represents the percentage of
variability in the estimates of additionally detected endoleaks
by MRI, which is attributable to heterogeneity between
studies rather than sampling error.
Furthermore, we examined the types of endoleaks that
were detected by MRI, but not seen at CTA. If available, data
were extracted on the ﬁve subtypes of endoleaks (Table 1).RESULTS
Search results
The electronic search yielded a total of 218 publications after
removal of duplicates. Nineteen full-text versions of studies
that matched the inclusion criteria were obtained. Six studies
were excluded: two case reports, two publications that
contained the same patient population, one article that did
not meet the language restriction (German article) and one
study that discussed thoracic EVAR (TEVAR) patients. Cross-
referencing of all included articles did not yield additional
articles. The ﬁnal selection of articles consisted therefore of
11 studies (Fig. 1). The detailed results of the quality
assessment for each study are given in Appendix II.
All included studies (Table 2) reported on the detection
of endoleaks in patients during follow-up after EVAR and
compared MRI with CTA ﬁndings. These 11 studies included
369 patients, who underwent at least one MRI and CTA
examination, with 562 MRI and 562 CTA examinations. The
interval between CTA and MRI should ideally be restricted
to 1 month. Most studies (n ¼ 7) reported a mean time
between MRI and CTA of 1 month or shorter. Two studies
exceeded the 1 month mean interval time between MRI
and CTA modality.5,11 Furthermore, two studies did not
explicitly report the time interval between both examina-
tions.10,12 The latter four studies were also included in the
Pubmed 
N = 121 
Embase 
N = 178 
N = 299 
N = 218 
Removal of duplicates 
N = 81 
N = 11 
Excluded after reading Full text 
N = 6 
Reasons of exclusion: 
Case report N=2 
Double publication N=2 
Non-English article N=1 
Thoracic aortic aneurysm N=1 
Included after cross 
referencing
N = 0 
N = 17 
Excluded after screening title + abstract 
N = 201 
Inclusion criteria: 
- Patients who underwent EVAR for AAA. 
- Imaging for the detection of endoleaks during follow up 
- Comparison of MRA with CTA.
Figure 1. Flowchart demonstrating search results and number of included and excluded studies.
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providing data on this topic. One study reported similar
proportions of additional endoleaks detected by MRI than
the other included studies. By contrast, the other study
detected relatively more additional endoleaks but this study
had a limited sample size (n ¼ 6).11 All MRI examinations
were performed on 1.5-T MRI systems, except in one study
in which a 1.0-T MRI system was used in some patients.13
All included studies performed arterial-phase imaging.
Delayed-phase CTA (60 s after contrast administration)
was performed in eight of 11 (73) studies (Table 2). In one
study not all patients received delayed-phased imaging.
Delayed-phase imaging was performed only in 13 patients
(13/28; 46%) with suspected endoleaks.14 One study did not
report the time interval between contrast administration
and delayed-phase imaging.11 Finally, in one study delayed
phase imaging was not performed.12 Detailed individual
information on patient characteristics and stent-graft type
was inconsistently reported in the different studies. The
available information is shown in Table 3. Overall, MRI
detected 278 endoleaks while CTA detected 146 endoleaks.
Thus, MRI detected 132 additional endoleaks compared to
CTA. MRI failed to detect two type I endoleaks: one prox-
imal type IA endoleak and one distal type IB endoleak.10,15
In Table 4, the number of additional endoleaks detected by
MRI in the different studies is presented.Patient population
In the analysis two different study populations were distin-
guished: (1) an unselected patient population (n¼ 10) and (2)
patients with no discernible endoleaks at CTA (n ¼ 1). One
study consisted of both unselected patients and patients with
known endoleaks on CTA.13 We considered pooling the
extracted data of the individual studies by examining an
unselected patient population. However, we refrained from
pooling because of large clinical heterogeneity based on the
QUADAS assessment and large statistical heterogeneity as
demonstrated by the I2 test in the unselected population e
81.1% (P value of Cochran’s Q statistic < 0.001). Therefore,
only estimates from individual studies are shown in Fig. 2. In
the single study that included patients with non-shrinking
AAA without visible endoleaks on CTA (population 2), MRI
detected six endoleaks (55%) (Fig. 2).16Endoleak types
The proportion of additional endoleaks detected by MRI was
classiﬁed into the different endoleak subtypes. In the unse-
lected patient population MRI detected a total of 128 addi-
tional endoleaks. The study of Insko et al. detected four
additional endoleaks with MRI in nine patients, but did not
specify which types of endoleaks were found.12 Therefore,
124 additional endoleaks detected by MRI could be classiﬁed
Table 2. Included studies.
Author, journal,
year
Number of
patients
included
(number of
scans)
Study
population
MRI Reference
mModality
Delayed phase
CTA (acquisition
time after start
contrast injection)
Mean time
between
MRI and
CTA (range)
No. and type of endoleaks
detected by MRI
No. and type of endoleaks
detected by CTA
Haulon, Eur. J.
Vasc. Endovasc.
Surg., 20015
31 (31) Unselected MRI
(1.5 T)
DSA Yes (60 s) 2.6 months
(1e6
months)
Total MRA: 18
Type I:1
Type II: 17
Total CTA: 10
Type I: 1
Type II: 9
Cejna, Eur. Radiol.,
200213
32 (40) Unselected MRI
(1.0 T or
1.5 T)
CTA Yes (60e70 s) 6.6 days
(0e28
days)
Total: 18
Type I/III: 6
Type II: 12
Uniphasic (n ¼
22 scans)
Total: 7
Type I/III: 3
Type II: 4
Biphasic (n ¼
18 scans)
Total: 8
Type I/III: 3
Type II: 5
Insko, Acad. Radiol.,
200312
9 (9) Unselected MRI
(1.5 T)
CTA No Not
reported
Total:6
Type I:2
Type II:4
Total: 4
Type I: 2
Type II: 2
Ayuso, J. Magn. Reson.
Imaging, 200426
27 (27) Unselected
(n ¼ 17)
Endoleaks
present
on CTA
(n ¼ 10)
MRI
(1.5 T)
CTA Yes (20e30 s after
arterial phase)
1e30 days Total: 21
Type II: 15
Type III: 3
Indeterminate: 3
Total: 16
Type II: 12
Type III 3
Indeterminate: 1
Ersoy, Am. J.
Roentgenol., 200411
6 (6) Unselected MRI
(1.5 T)
CTA Yes (NR) 90 days (5e
203 days)
Total: 6 Total: 2
Pitton, Am. J.
Roentgenol., 200410
52 (252) Unselected MRI
(1.5 T)
Consensus
reading of
CTA and
MRI
Yes (90 s) Not
reported
Total MRA: 131
Type I: 7
Type II: 93
Type III: 21
Complex: 10
Total CTA: 62
Type I: 8
Type II: 42
Type III: 10
Complex 2
Van der Laan,
Eur. J. Vasc.
Endovasc.
Surg., 200614
28 (35) Unselected MRI
(1.5 T)
CTA Yes (120 and
240 s) in
patients
with
suspected
endoleak
Max 1
month
Total: 23
Type I: 2
Type II: 6
Type III: 1
Indeterminate 14
Total: 11
Type I: 2
Type II: 3
Type III: 1
Indeterminate: 5
Alerci, Eur. Radiol.,
200815
43 (43) Unselected MRI
(1.5 T)
CTA
Consensus
reading of
CTA and
MRI
Yes (60 s) Max 1
week
Observer 1
Total: 22
Type II: 19
Indeterminate: 3
Observer 2
Total: 24
Type II: 13
Indeterminate: 11
Observer 1
Total: 11
Type II: 10
Type V: 1
Observer 2
Total: 12
Type I: 1
Type II: 7
Indeterminate: 4
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344 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 4 April/2013per endoleak type. This resulted in the following distribution
of additional endoleaks detected by MRI: 86 type II (69%); 12
type III (10%) and 26 indeterminate endoleaks (21%). Data on
type II subtype (IIa and IIb) were not provided inmost studies
and therefore not addressed in this meta-analysis. A total of
two endoleaks were detected by CTA and missed by MRI.
Both these leaks were type 1 endoleaks.10,15DISCUSSION
The principal ﬁnding of this systematic review is that MRI
detects signiﬁcantly more endoleaks compared to CTA in
patients after EVAR, especially type II endoleaks. The detec-
tion of these additional type II endoleaks is clinically relevant
because these endoleaks require treatment in patients with
aneurysm growth according to both the Society for Vascular
Surgery (SVS) as well as European Journal of Vascular and
Endovascular Surgery (EJVES) guidelines.4,8
Methodological quality assessment revealed several
potentially relevant differences between included studies.
First, mean time interval between CTA and MRI exceeded 1
month in two studies5,11 and was unclear in two studies.10,12
Longer time interval between CTA and MRI may increase the
detection of additional endoleaks by MRI because during this
time interval new endoleaks could have developed or
increased in volume or severity. We decided to include these
studies because of the limited available data on this topic.
Second, in the majority of included studies (8/11; 73%), the
presence of endoleak was assessed on delayed-phase CTA.
For the detection of type II endoleaks, delayed-phase imaging
is crucial and the absence of delayed-phase imaging could
have resulted in overestimation of the additional value ofMRI
for the detection of endoleaks. Three other QUADAS items
deserve to bementioned (Appendix II).The ﬁrst item (item 12,
Appendix II) concerns the availability of clinical data during
MRI assessment.This itemwas scored ‘unclear’ in nine studies
and ‘no’ in two studies. However, for accurate MRI and CTA
assessment, the availability of clinical data is not a strict
necessity. The second item (reporting of uninterpretable and
intermediate test results; item 13, Appendix II) was scored
‘yes’ in three studies and ‘no’ in eight studies. Appropriate
reporting of these results is relevant because in clinical
practice it is important to know if image quality is adequate to
assess endoleak presence because it may guide treatment
decisions. The last item (explanation on withdrawals from the
study; item 14, Appendix II) was scored ‘yes’ in three studies
and ‘no’ in eight studies. Reporting of withdrawals is impor-
tant because, for clinical implementation of MRI in EVAR
follow-up, it is important to know if patients tolerate the MR
examination and administration of MR contrast agents.
Overall, MRI examinations demonstrated 126 additional
endoleaks compared to CTA. However, MRI missed two type
I endoleaks that were detected by CTA.10,12 One distal type I
endoleak (IB) was masked because of vessel-wall calciﬁca-
tions and platinummarkers of the distal limb stent graft. This
type I endoleak was detected with a triphasic CTprotocol. On
the unenhanced scan, calciﬁcations were identiﬁed and
could be differentiated from the endoleak present on the
Table 3. Study characteristics.
Author, journal,
year
Mean max AAA
diameter (range)
Stentgraft
type
Male/female
ratio
Mean age in
years (range)
MRI contrast
agent type
MRI T1-weighted
sequence type
Haulon, Eur. J.
Vasc. Endovasc.
Surg., 20015
49 mm 25 Vanguard;
4 AneuRx; 2
Talent
30/1 64 (47e77) Gadolinium
based
extracellular
Spin echo
Cejna, Eur.
Radiol., 200213
Not reported 3 Talent; 7
Excluder; 30
Stentor and
Vanguard
29/3 72 (58e84) Gadolinium
based
extracellular
Gradient echo
Insko, Acad.
Radiol., 200312
Not reported 8 Medtronic
nitinol; 1
elgiloy
Guidant
Not reported Not reported Gadolinium
based
extracellular
Gradient echo
Ayuso, J. Magn.
Reson. Imaging,
200426
CTA: 56.7 mm
(39e93)
MRA: 58.8 mm
(37e96)
4 Talent; 20
Excluder; 2
Vanguard; 2
AneuRx
Not reported Not reported Gadolinium
based
extracellular
Gradient echo
Ersoy, Am. J.
Roentgenol l.,
200411
50 mm (44e65) AneuRx;
Ancure
6/1 62e83 Albumin-
binding
Not reported
Pitton, Am. J.
Roentgenol.,
200410
Not reported Talent;
Vanguard
48/4 71.1 (55e82) Gadolinium
based
extracellular
Gradient echo
Van der Laan,
Eur. J. Vasc.
Endovasc.
Surg., 200614
Not reported 3 Excluder;
25 Ancure
26/2 72.3 Gadolinium
based
extracellular
Spin echo
Alerci, Eur.
Radiol., 200815
58 mm (50e74) 13 Talent;
30 Excluder
41/2 Not reported Albumin-
binding
Gradient echo
Cornelissen,
Invest. Radiol.,
201016
60 mm (41e87) 9 Talent; 1
Excluder; 2
Guidant (1
AUI and 1
Ancure)
10/2 76.6 (62e90) Albumin-
binding
Spin echo
Wieners,
Cardiovasc.
Interv. Radiol.,
201017
CTA: 52.5 mm
(24e84)
MRI: 52.8 mm
(24e86)
25 Excluder; 4
Talent; 3
Anaconda
Not reported 76 (64e86) Albumin-
binding
Gradient echo
Cantisani,
Eur. J. Vasc.
Endovasc.
Surg., 201127
54 mm (39e87) 55 Talent; 50
Excluder; 12
Powerlink;
6 Jomed
92/31 63.0 Gadolinium
based
extracellular
Gradient echo
J. Habets et al. 345CTA images. Alerci et al. reported on the second missed type
I endoleak (only one of two observers mentioned this
endoleak).15 However, their consensus reading (MRI þ CTA)
concluded that there was no type I endoleak on both CTA
and MRI. We chose to use the numbers of endoleaks of the
second observer because they were most close to the
consensus reading. In clinical practice, it is crucial to detect
type I endoleaks because they often result in AAA growth
and may even lead to aneurysm rupture. Besides these two
type I endoleaks, MRI and CTA detected both all type I
endoleaks. Furthermore, we would like to emphasise that we
view MRI as a complementary technique to CTA in the case
of aneurysm growth. Therefore, the missed type I endoleaks
are less relevant because in our proposed diagnostic strategy
CTA would probably have detected these endoleaks (Fig. 3).
Nowadays, type III endoleaks due to graft failure are
infrequently encountered because of the new-generationnitinol stent grafts, longer overlap zones between the
modular components and stronger polyester fabrics. MRI
detected all type III endoleaks detected by CTA. However,
Pitton et al. detected 11 additional type III endoleaks with
MRI compared to CTA.10 Type III endoleaks are fast-ﬂow
endoleaks that require appropriate treatment. In this study,
only two patients who underwent re-intervention had
a negative biphasic CTA examination and an additional
endoleak onMRI.10 These two patients had a type II endoleak
that was embolised and a type III endoleak (dislodgement
due to kinking of the stent graft) that required late conver-
sion. Although 11 additional type III endoleaks were found by
MRI, treatment of a type III endoleak was only reported in
one patient. This is in contrast to current guidelines that
recommend treating all type III endoleaks.4,8 However, it is
unclear how many times this patient was imaged because
MRI was a part of the standard follow-up protocol.
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Table 4. Endoleaks detected by different studies, speciﬁed by type (unselected patients).
Author Year Patients (N) Scans (n) MRI: total
endoleaks
MRI: endoleaks by type Reference: total
endoleaks
Reference: endoleaks by type
I II III IV V Indeter-
minate
I II III IV V Indeter-
minate
Haulon et al.5 2001 31 31 18 1 17 0 0 0 0 10c 1 9 0 0 0 0
Cejna et al.13 2002 32 18 9b 1 6 1 0 0 1 8b 1 5 1 0 0 1
Insko et al.12 2003 9 9 6 2 4 0 0 0 0 4 2 2 0 0 0 0
Ayuso et al.26 2004 17 17 10 0 6 1 0 0 3 5 0 3 1 0 0 1
Ersoy et al.11 2004 6 6 6 NR NR NR NR NR NR 2 NR NR NR NR NR NR
Pitton et al.10 2005 52 252 131 7 93 21 0 0 10 62c 8 42 10 0 0 2
Van der Laan et al.14 2006 28 35 23 2 6 1 0 0 14 11 2 3 1 0 0 5
Alerci et al.15,a 2009 43 43 24 0 13 0 0 0 11 12c 1 7 0 0 0 4
Wieners et al.17 2010 32 32 21 0 21 0 0 0 0 12 0 12 0 0 0 0
Cantisani et al.27 2011 108 108 24 0 21 3 0 0 0 20c 0 18 2 0 0 0
Total 358 551 272 13 187 27 0 0 39 146 15 101 15 0 0 13
NR: Not reported.
a Only results of observer 2.
b Endoleaks detected on biphasic CTA’s and compared to MRI. Endoleaks detected on uniphasic CTA’s are not shown in this table.
c Number of endoleaks detected on CTA (Reference standard in this studies was deﬁned as consensus reading between MRI and/or CTA and/or DSA).
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J. Habets et al. 347compared to CTA for the detection of endoleaks, especially
type II endoleaks. The main reason for this ﬁnding is prob-
ably the superior MRI soft-tissue contrast and, subsequently,
the improved contrast sensitivity for small and slow-ﬂow
endoleaks. Furthermore, in four studies (4/11; 36%),
albumin-binding contrast agents were administered, which
are characterised by a higher relaxivity (2e5 times higher)
compared to conventional extracellular agents.11,15e17
These contrast agents have a prolonged intravascular
retention in the circulation that allows a longer time interval
between contrast administration and post-contrast
imaging.18,19 Both higher relaxivity and prolonged intravas-
cular retention could have improved the sensitivity of MRI.
The bulk of additional endoleaks detected with MRI con-
cerned type II endoleaks. Unfortunately, individual data on
aneurysm growth was lacking, which is crucial for treatment
decisions because type II endoleaks which cause AAA diameter
growth require treatment according to current guidelines.4,8
Although Wieners et al. reported that six of nine (67%) addi-
tional endoleaks onMRI occurred in patientswith AAA growth,
further prospective studies are required to determine the exact
value of MRI in patients with AAA growth.17 Furthermore,
Cornelissen et al. detected two additional type II endoleaks in
patients with AAA growth with MRI among 11 patients with
non-shrinking AAA after EVAR and no endoleak at CTA.16Limitations
Meta-analysis was not meaningful because of the large
heterogeneity in the included studies. Besides the previously
mentioned AAA growth, several other interesting covariates
(stent-graft type, the use of albumin-binding contrast agents
and the use of T1 spin-echo sequences) could not be analysed
because of the large heterogeneity and the lack of individual
data in the study reports. Most studies concerned patients
with nitinol stent grafts that generally did not hamper
assessment (Table 3). It is well known that other stent-graft
types (Elgiloy and stainless steel) can hamper diagnostic MR
assessment because of metal-induced susceptibility artefacts,
even when T1 spin-echo sequences are used. These stent-
graft types are not good candidates forMRevaluation. Prior in
vitro work demonstrated that Zenith (Stainless Steel; Cook,
Bloomington, IN, USA) and Lifepath (Elgiloy; Baxter, Morton
Grove, IL, USA) stent grafts are not assessable by MRI.20 For
these stent-graft types, CTA and contrast-enhanced ultra-
sound remain the preferred imaging modalities.
The use of albumin-binding high-relaxivity contrast agents
as well as T1-weighted spin-echo post-contrast MR imaging
seem to increase sensitivity for the detection of endoleak.15e
17 Albumin-binding contrast agents could be promising for
the detection of slow-ﬂow endoleaks in patients with aneu-
rysm growth and no endoleaks on CTA because of the pro-
longed intravascular retention as well as the higher relaxivity.
In the included studies, mainly nitinol stent grafts were
imaged and especially for other stent-graft types (e.g., Elgiloy
and stainless steel) T1-weighted spin-echo sequencesmay be
preferable because images are less affected by susceptibility
artefacts.20 Nevertheless, prospective studies are required todetermine the exact value of albumin-binding contrast
agents and T1-weighted spin-echo sequences.
Besides CTA, contrast-enhanced ultrasound is used to detect
endoleaks in patients after EVAR. A meta-analysis by Mirza
et al. reported a good pooled sensitivity (98%) and speciﬁcity
(88%) of contrast-enhanced ultrasound with CTA used as
a reference standard.21 This meta-analysis shows that contrast-
enhanced ultrasound is a clinically interesting alternative to
CTA. However, for the evaluation of stent-graft position and
fractures, contrast-enhanced ultrasound is inferior to CTA.22
Time-resolved MR angiography (MRA) sequences can also
be used to detect endoleaks. The advantage of this type of
sequence is the superior temporal resolution, which enables
better assessment of contrast dynamics over time. The disad-
vantage of this sequence is the generally inferior spatial reso-
lution compared to conventional post-contrast T1-weighted
imaging, which can potentially result in missing small endo-
leaks. Furthermore, time-resolved acquisitions are based on
gradient echo sequences, which are more sensitive to
susceptibility artefacts that can degrade image quality.
However, time-resolved MRA may have an additional diag-
nostic value to T1-weighted post-contrast imaging in the clas-
siﬁcation of endoleaks and can be combined with conventional
T1-weighted imaging without signiﬁcant time penalty.23e25
For MRI imaging of endoleaks with blood pool agents, no
standard MRA sequences are reported in the literature. For
comparability of studies and to reduce heterogeneity, it is
important that in prospective studies MRA sequences are
standardised to extrapolate results to clinical practice.
In this review, studies were included that compared CTA to
MRI T1-weighted post-contrast imaging. Veriﬁcation with an
independent reference standard (e.g., digital subtraction
angiography, DSA) was not systematically performed in the
included studies. However, DSA may also miss endoleaks
especially when non-selective DSA is performed. Prospective
studies are required to compare CTA andMRI to selective DSA.
Finally, it is important to mention that metal-induced
susceptibility artefacts due to surgical clips and stainless-steel
coils can also hamper MRI assessment of post-EVAR patients.
MR-compatible clips and coil material (i.e., platinum) are
advisable ifMRI follow-up is considered. It is also important to
mention that not all patients are good candidates forMRI due
to contraindications such as claustrophobia, certain other
types of metal implants and the presence of implanted
pacemakers or internal cardioverter/deﬁbrillators.
CONCLUSION
MRI is more sensitive than CTA for the detection of post-
EVAR endoleaks, especially for the detection of type II
endoleaks which has treatment consequences in patients
with AAA growth. MRI is therefore an interesting comple-
mentary imaging modality to CTA that must be considered,
especially in patients with post-EVAR AAA growth of
unknown origin.
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APPENDIX I.
Exact search terms used in literature search.
Pubmed: 121 articles
((‘MRA’[Title/Abstract] OR ‘MRI’[Title/Abstract] OR ‘Magnetic Resonance Imaging’[Title/Abstract] OR ‘Magnetic Resonance Angiography’[Title/Abstract] OR ‘Magnetic Resonance
Angiographies’[Title/Abstract] OR ‘Magnetic Resonance Imaging’[Mesh] OR ‘Magnetic Resonance Angiography’[Mesh])
AND
(‘endoleak’[Title/Abstract] OR ‘endoleaks’[Title/Abstract] OR ‘Perigraft Leak’[Title/Abstract] OR ‘perigraft leaks’[Title/Abstract] OR ‘endotension’[Title/Abstract] OR ‘endoleak’[Mesh]))
AND
((‘EVAR’[Title/Abstract] OR ‘endovascular’[Title/Abstract] OR ‘aneurysm repair’[Title/Abstract] OR ‘aneurysm surgery’[Title/Abstract]
OR ‘aortic stent’[Title/Abstract]) OR ‘aortic stent graft’[Title/Abstract] OR ‘AAA’[Title/Abstract] OR ‘aortic aneurysm’[Title/Abstract]
OR ‘aortic aneurysms’[Title/Abstract] OR ‘aorta aneurysm’[Title/Abstract] OR ‘aorta aneurysms’[Title/Abstract] OR ‘Aortic Aneurysm, Abdominal’[Mesh] OR ‘Aortic Aneurysm’[Mesh])
Embase: 178 articles
(‘nuclear magnetic resonance imaging’/exp OR ‘magnetic resonance angiography’/exp OR mra:ab,ti OR mri:ab,ti OR (magnetic AND resonance AND imaging:ab,ti) OR (magnetic AND
resonance AND angiography; ab,ti) OR (magnetic AND resonance AND angiographies; ab,ti))
AND
(endoleak; ab,ti OR endoleaks:ab,ti OR (perigraft AND leak:ab,ti) OR (perigraft AND leaks:ab,ti) OR endotension:ab,ti OR ‘endoleak’/exp)
AND
(‘abdominal aorta aneurysm’/exp OR ‘abdominal aorta aneurysm’ OR ‘endovascular surgery’/exp OR ‘endovascular surgery’ OR ‘aorta aneurysm’/exp OR ‘aorta aneurysm’ OR evar:ab,ti
OR endovascular:ab,ti OR (‘aneurysm’/exp OR aneurysm AND repair:ab,ti) OR (‘aneurysm’/exp OR aneurysm AND surgery:ab,ti) OR (aortic AND stent:ab,ti) OR (aortic AND (‘stent’/exp OR
stent) AND graft:ab,ti) OR aaa:ab,ti OR (aortic AND aneurysm:ab,ti) OR (aortic AND aneurysms:ab,ti) OR (‘aorta’/exp OR aorta AND aneurysm:ab,ti) OR (’aorta’/exp OR aorta AND
aneurysms:ab,ti))
APPENDIX II.
Quality of the studies based on the criteria as proposed by the QUADAS checklists.
Author, journal, year Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Item 12 Item 13 Item 14
Haulon, Eur. J. Vasc. Endovasc. Surg., 2001 Yes Yes Yes (DSA) No No Yes Yes Yes Yes Yes Yes Unclear No No
Cejna, Eur. Radiol., 2002 Yes Unclear Yes (CTA) Yes Unclear Yes Yes Yes Yes Yes Yes Unclear No Yes
Insko, Acad. Radiol., 2003 Yes No Yes (CTA/DSA) Yes Yes No Yes Yes Yes Unclear Unclear Unclear No No
Ayuso, J. Magn. Reson. Imaging, 2004 Yes/No Yes Yes (CTA) Yes Yes Yes Yes Yes Yes Yes Yes Unclear No No
Ersoy, Eur. J. Radiol., 2004 Yes Yes Yes (CTA) No Yes Yes Yes Yes No Unclear Unclear Unclear No Yes
Pitton, Am. J. Roentgenol., 2004 Yes Yes Yes (CTA) Unclear Yes Yes No Yes Yes Yes No Unclear Yes No
Vd Laan, Eur. J. Vasc. Endovasc. Surg., 2006 Yes Yes Yes (CTA) Yes Yes Yes Yes Yes Yes Yes Yes Unclear No No
Alerci, Eur. Radiol., 2008 Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes No Yes No
Cornelissen, Invest. Radiol., 2010 No Yes Yes (CTA) Yes No Yes Yes Yes Yes Yes Yes No Yes Yes
Wieners, Cardiovasc. Interv. Radiol., 2010 Yes No Yes (CTA) Yes Yes Yes Yes Unclear Unclear Yes Yes Unclear No No
Cantisani, Eur. J. Vasc. Endovasc. Surg., 2011 Yes Yes Unclear Yes Unclear Unclear Yes Yes Yes Yes Yes Unclear No No
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J. Habets et al. 349Questions according to the different items:
1. Was the spectrum of patients representative of the
patients who will receive the test in practice?
2. Were selection criteria clearly described?
3. Is the reference standard likely to correctly classify the
target condition?
4. Is the time period between reference standard and
index test short enough to be reasonably sure that
the target condition did not change between the two
tests?
5. Did the whole sample or a random selection of the
sample, receive veriﬁcation using a reference
standard of diagnosis?
6. Did patients receive the same reference standard
regardless of the index test result?
7. Was the reference standard independent of the index
test (i.e., the index test did not form part of the
reference standard)?
8. Was the execution of the index test described in
sufﬁcient detail to permit replication of the test?
9. Was the execution of the reference standard described
in sufﬁcient detail to permit its replication?
10. Were the index test results interpreted without
knowledge of the results of the reference standard?
11. Were the reference standard results interpreted
without knowledge of the results of the index test?
12. Were the same clinical data available when test results
were interpreted as would be available when the test
is used in practice?
13. Were uninterpretable/intermediate test results
reported?
14. Were withdrawals from the study explained?
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